Regulatory actions for Oct. 2, 2025Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Bristol Myers Squibb, Cour, Cyprium, Ensem, Evofem, Fortress, Novartis, Pharma 1, Pharming, Sentynl, Taho.